尼妥珠单抗联合同步放化疗对晚期宫颈癌患者病灶癌细胞增殖基因mRNA表达量及Ep-CAM、Ki67阳性表达情况的影响  

Effects of nituzumab combined with concurrent chemoradiation on the expression of proliferation gene mRNA in focal cancer cells and the positive expression of Ep-CAM and Ki67 in patients with advanced cervical cancer

作　　者：赵钦 王虹伊 ZHAO Qin;WANG Hongyi(Xi'an International Medical Center Hospital,Xi'an 710100,China)

机构地区：[1]西安国际医学中心医院,陕西西安710100

出　　处：《临床医学研究与实践》2022年第11期28-31,共4页Clinical Research and Practice

摘　　要：目的探讨尼妥珠单抗联合同步放化疗治疗晚期宫颈癌患者的临床效果。方法选取2018年1月至2020年10月收治的68例晚期宫颈癌患者作为研究对象,以抽签法将其分为对照组和观察组,各34例。对照组采用同步放化疗治疗,观察组采用尼妥珠单抗联合同步放化疗治疗。比较两组的病灶癌细胞增殖基因mRNA表达量、Ep-CAM、Ki67阳性表达情况、临床疗效、不良反应发生情况。结果治疗前,两组的B7-H4、PCNA、HIF-1α、FHIT、PTEN、STC1 mRNA表达量比较,差异无统计学意义(P>0.05);治疗后,观察组的B7-H4、PCNA、HIF-1αmRNA表达量低于对照组,FHIT、PTEN、STC1 mRNA表达量高于对照组,差异具有统计学意义(P<0.05)。治疗后,观察组的Ep-CAM、Ki67阳性表达率低于对照组,差异具有统计学意义(P<0.05)。观察组的治疗总有效率为88.24%,高于对照组的67.65%,差异具有统计学意义(P<0.05)。两组的恶心呕吐、白细胞减少、放射性直肠炎、放射性膀胱炎发生率比较,差异无统计学意义(P>0.05)。结论尼妥珠单抗联合同步放化疗治疗晚期宫颈癌患者可改善病灶癌细胞增殖基因mRNA表达量,减少Ep-CAM、Ki67阳性表达,提高临床疗效,且不会明显增加不良反应。Objective To investigate the clinical effect of nituzumab combined with concurrent chemoradiation in the treatment of patients with advanced cervical cancer.Methods A total of 68 patients with advanced cervical cancer treated from January 2018 to October 2020 were selected as the research objects,and the patients were divided into control group and observation group by lot,with 34 cases in each group.The control group was treated with concurrent chemoradiation,and the observation group was treated with nituzumab combined with concurrent chemoradiation.The expression of proliferation gene mRNA in focal cancer cells,positive expression of Ep-CAM and Ki67,clinical efficacy and occurrence of adverse reactions were compared between the two groups.Results Before treatment,there were no significant differences in the expression of B7-H4,PCNA,HIF-1α,FHIT,PTEN and STC1 mRNA(P>0.05);after treatment,the expression of B7-H4,PCNA,HIF-1αmRNA in the observation group were lower than those in the control group,the expression of FHIT,PTEN and STC1 mRNA in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the positive expression rates of Ep-CAM and Ki67 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total effective rate of treatment in the observation group was 88.24%,which was higher than 67.65%in the control group,and the difference was statistically significant(P<0.05).There were no significant differences in the incidences of nausea and vomiting,leucopenia,radiation proctitis and radiation cystitis between the two groups(P>0.05).Conclusion Nituzumab combined with concurrent chemoradiation in the treatment of patients with advanced cervical cancer can ameliorate the expression of proliferation gene mRNA in focal cancer cells,reduce the positive expression of Ep-CAM and Ki67,improve the clinical efficacy,and do not significantly increase the adverse react

关 键 词：尼妥珠单抗 同步放化疗 晚期宫颈癌 

分 类 号：R73[医药卫生—肿瘤]